Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

By J. Orgogozo, S. Gilman, Jean-François Dartigues, Bernard Laurent, M. Puel, L. Kirby, P. Jouanny, Bruno Dubois, L. Eisner, S. Flitman and 4 more. Neurology, 2003

1,403 citations recorded by the source corpus.

Subfields: Neurology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/93b5e3385538e38d1a8c870eb399f6885e1aab64

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. C. Zhong
2. Zhichun Chen

In Physiology

1. Dan Xiao
2. Weifeng Zhang
3. Haibin Xia
4. Q. Mao
5. C. Zhong
6. Zhichun Chen

In Psychiatry and Mental health

1. C. Zhong
2. Zhichun Chen

Citations in the corpus

• Role of neuroinflammation in neurodegeneration development (2023, result): “Immunization of AD patients with first-generation Aβ vaccines greatly reduced amyloid aggregation, but did not stop disease progression, even leading to the development of meningoencephalitis.(525) These results prompt the development of second generation Aβ vaccines that limit the induction of self”
• Therapeutics of Alzheimer's disease: Past, present and future. (2014, background): “During the trial about 6% of subjects developed meningoencephalitis hence, was discontinued (Orgogozo et al., 2003).”
• Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. (2013, background): “are not demonstrated to show more significance efficacy than control placebo, though some of them effectively clear Ab deposits in AD brain (Gravitz, 2011; Holmes et al., 2008; Gilman et al., 2005; Orgogozo et al., 2003).”